Lonidamine and radiotherapy in head and neck cancers. A pilot study.
The tolerance and antitumor activity of Lonidamine combined with radiotherapy were studied on 40 patients with head and neck cancer and compared with a historical control group. Lonidamine was well tolerated. 26 and 17 complete responses were seen in the Lonidamine-treated group and in the historical control group, respectively.
D000970:Antineoplastic Agents; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D007191:Indazoles / Q000627:therapeutic use*; D008297:Male; D011720:Pyrazoles / Q000627:therapeutic use*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D007191:Indazoles; D011720:Pyrazoles; D011838:Radiation-Sensitizing Agents; C016371:lonidamine